| Previous close | 179.32 |
| Open | 179.26 |
| Bid | 179.01 x 100 |
| Ask | 180.21 x 200 |
| Day's range | 179.16 - 180.55 |
| 52-week range | 133.64 - 184.21 |
| Volume | 2,674,714 |
| Avg. volume | 3,397,239 |
| Market cap | 132.53B |
| Beta | 1.76 |
| PE ratio (TTM) | 17.12 |
| EPS (TTM) | 10.53 |
| Earnings date | 25 Jul 2017 |
| Dividend & yield | 4.60 (2.57%) |
| Ex-dividend date | 2017-05-15 |
| 1y target est | 182.41 |
- The Wall Street Journal•9 hours ago
[$$] Clinical Development News, July 17-21
The following is a list of clinical development news from private and public companies during the week of July 17-21.
- GuruFocus.com•13 hours ago
FDA Accepts Amgen's Biologics License Application for Aimovig
The target action date is in May 2018
- Barrons.com•15 hours ago
Will Gilead Beat 2Q Earnings? Perhaps…But Does It Matter?
Is Gilead Sciences (GILD) poised for a beat next week? Guggenheim analyst Tony Butler sees Gilead earning $2.15 a share, a penny above the consensus forecast compiled by sell-side analyst, with operating revenue of $6.54 billion beating the $6.31 billion expected by the Street. Butler’s estimates for the full 2017 calendar year are also above consensus, with per-share earnings of $8.28 on operating revenue of $25.4 billion.
